Compare Danaher Corporation (DHR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs McKesson Corporation — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while McKesson Corporation trades at $801.97 (market cap $94.06B). The key difference: Danaher Corporation is the larger of the two by market cap, and Danaher Corporation pays the higher dividend (0.8%). Which is the better fit depends on your goals.
| DHR | MCK | |
|---|---|---|
Market Cap | $140.88B | $94.06B |
Sector | Health | Health |
52-Week High | $242.05 | $995.69 |
52-Week Low | $161.91 | $659.01 |
Enterprise Value | $153.66B | $98.70B |
Dividend Yield | 0.8% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
